William Blair Has Positive Outlook of OCUL FY2025 Earnings

Key Points

• William Blair has revised their FY2025 EPS estimate for Ocular Therapeutix to ($1.53), an improvement from the previous forecast of ($1.60).
• Multiple analysts have provided positive ratings for Ocular Therapeutix, with eight analysts reflecting a consensus rating of "Buy" and an average target price of $20.33.
• Ocular Therapeutix recently reported a $13.46 million revenue for the previous quarter, despite a year-over-year decline of 17.7%.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities researchers at William Blair upped their FY2025 EPS estimates for shares of Ocular Therapeutix in a note issued to investors on Wednesday, October 1st. William Blair analyst L. Hanbury-Brown now expects that the biopharmaceutical company will post earnings per share of ($1.53) for the year, up from their prior forecast of ($1.60). The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. William Blair also issued estimates for Ocular Therapeutix's Q4 2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.58) EPS.

OCUL has been the subject of several other research reports. Citigroup restated an "outperform" rating on shares of Ocular Therapeutix in a research note on Wednesday. Chardan Capital restated a "buy" rating and issued a $21.00 price objective on shares of Ocular Therapeutix in a research report on Thursday. JMP Securities increased their target price on Ocular Therapeutix from $20.00 to $29.00 and gave the company a "market outperform" rating in a research report on Wednesday. Scotiabank dropped their price target on shares of Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, August 6th. Finally, Needham & Company LLC upped their price objective on shares of Ocular Therapeutix from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $20.33.

Ocular Therapeutix Trading Up 0.2%

Shares of Ocular Therapeutix stock opened at $11.06 on Friday. The firm has a 50-day simple moving average of $12.31 and a two-hundred day simple moving average of $9.69. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.02 and a current ratio of 10.10. Ocular Therapeutix has a fifty-two week low of $5.78 and a fifty-two week high of $13.85. The company has a market cap of $1.92 billion, a P/E ratio of -8.64 and a beta of 1.45.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The firm had revenue of $13.46 million during the quarter, compared to analyst estimates of $13.12 million. During the same quarter in the prior year, the firm earned ($0.26) earnings per share. The business's revenue for the quarter was down 17.7% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC lifted its position in Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 1,392 shares in the last quarter. Brooklyn Investment Group increased its stake in shares of Ocular Therapeutix by 151.5% in the 1st quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 3,155 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Ocular Therapeutix by 17.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 893 shares during the period. GAMMA Investing LLC boosted its position in shares of Ocular Therapeutix by 6,760.0% during the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 8,112 shares during the last quarter. Finally, Trust Co. of Vermont grew its holdings in shares of Ocular Therapeutix by 16.1% in the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company's stock valued at $67,000 after purchasing an additional 1,000 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, insider Jeffrey S. Heier sold 3,063 shares of the business's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $12.04, for a total transaction of $36,878.52. Following the transaction, the insider directly owned 259,911 shares in the company, valued at approximately $3,129,328.44. The trade was a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Pravin Dugel sold 21,494 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $12.04, for a total transaction of $258,787.76. Following the sale, the insider directly owned 3,227,244 shares of the company's stock, valued at approximately $38,856,017.76. This represents a 0.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,519 shares of company stock valued at $367,865 in the last 90 days. 2.30% of the stock is owned by insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.